Reviewing Poxel France (OTCMKTS:PXXLF) & X4 Pharmaceuticals (NASDAQ:XFOR)

X4 Pharmaceuticals (NASDAQ:XFOR) and Poxel France (OTCMKTS:PXXLF) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Profitability

This table compares X4 Pharmaceuticals and Poxel France’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-279.86%	-343.67%	-69.77%
Poxel France	N/A	N/A	N/A

Insider & Institutional Ownership

72.0% of X4 Pharmaceuticals shares are held by institutional investors. 2.2% of X4 Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for X4 Pharmaceuticals and Poxel France, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1	0	3	1	2.80
Poxel France	0	0	0	0	0.00

X4 Pharmaceuticals currently has a consensus target price of $33.67, indicating a potential upside of 819.85%. Given X4 Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe X4 Pharmaceuticals is more favorable than Poxel France.

Earnings & Valuation

This table compares X4 Pharmaceuticals and Poxel France”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$2.56 million	125.01	-$37.45 million	($10.13)	-0.36
Poxel France	$710,000.00	10.19	-$33.08 million	N/A	N/A

Poxel France has lower revenue, but higher earnings than X4 Pharmaceuticals.

Risk and Volatility

X4 Pharmaceuticals has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Poxel France has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500.

Summary

X4 Pharmaceuticals beats Poxel France on 8 of the 13 factors compared between the two stocks.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

About Poxel France

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.